Hermesdorf, Marco http://orcid.org/0000-0003-3541-7212
Wulms, Niklas
Maceski, Aleksandra
Leppert, David
Benkert, Pascal
Wiendl, Heinz
Kuhle, Jens
Berger, Klaus
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (FKZ-01ER0816, FKZ-01ER1506, FKZ-01ER1205)
Westfälische Wilhelms-Universität Münster
Article History
Received: 10 November 2022
Accepted: 24 May 2023
First Online: 7 June 2023
Declarations
:
: D.L. is Chief Medical Officer of GeNeuro. H.W. received grants from the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Deutsche Myasthenie Gesellschaft e.V., Alexion, Amicus Therapeutics Inc, Argenx, Biogen, CSL Behring, F. Hoffman-La Roche, Genzyme, Merck KgaA, Novartis Pharma, Roche Pharma, and UCB Biopharma. H.W. received payment or honoraria from Alexion, Amicus Therapeutics, Biogen, Biologix, Bristol Myers Squibb, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Gen Medicine, Medison, Merck, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. H.W. participated on a data safety monitoring board or advisory board for Argenx, and PSI CRO. J.K. received grants from the Swiss National Science Foundation and Octave Biosciences. J.K. received consulting fees from Biogen, Novartis, Octave, Roche, and Sanofi. K.B. received grants from the BMBF. All other authors have no competing interest to declare.